A plant derived formulation for the treatment of chronic and acute bronchitis and sinusitis. With
evidence based studies supporting its efficacy in improving the function of mucociliary clearance, Health Vision Enterprise (HVE) has created a unique category position in China for this product and it is the drug of choice in ENT with CAGR of above 18% since its launch in China in 1996. Ranked 2nd in the market (R05C, IMS) with high brand loyalty, Gelomyrtol is well positioned in the ENT and respiratory sector.
China is showing a growing incidence rate of 10-15% in allergic rhinitis most likely due to industrialization. With the increase in purchasing power, patients seeking treatment of this common ailment will increase. The antihistamine market has grown from RMB 299million in 2004 to RMB 447million in 2007 with a CAGR of 16%. Azep Nasal Spray provides fast relief for seasonal and perennial allergic rhinitis symptoms such as runny nose, sneezing, itchy nose and congestion. It also provides a platform for other Azep formulations to be launched in the coming years.
A unique double action formulation to rapidly relieve pain and facilitate healing of mouth ulcers. Having just recently been launched in China in 2007, the product is highly praised by dentists and patients and shows good potential in the oral mouth ulcer market that covers both the OTC and hospital sector.
Human plasma derived fibrin sealant to control blood loss following surgical procedures. Still in the launch phase, key targets include liver, cardiac-thoracic & O&G surgical procedures. Fibinglu provides significant advantage compared to other alternatives and RAAS, the manufacturer is reputed for setting the highest standards in blood product manufacturing in China.
Used for the treatment of diabetic polyneuropathy. Positioned as the branded product of alpha lipoic acid, HVE has successfully obtained the price reserved for "branded" products in the majority of tenders and is the market leader in the alpha lipoic acid market. To strengthen sales and marketing activities on July 30th 2008, HVE signed a sublicensing agreement with Eisai China Inc. for the promotion of the product.
For fast relief of angina chest pain, it is the only nitroglycerin spray formulation with FDA approval. Because of its low alcohol formulation Nitrolingual Spray has high brand loyalty among users.
<< Click here for more >>